Using Clustered Regularly Interspaced Short Palindromic Repeats for Recombinant Biosynthesis of Antimicrobial Peptides as Anti-COVID-19 Agents.
Sherif M ElnagdyMaha AlKhazindarPublished in: ACS pharmacology & translational science (2022)
The SARS-CoV-2 pandemic has caused the death of 5.5 million people and the infection of more than 323 million people as of January 2022. The remarkable increase in pathogenicity and virulence might have occurred as a result of viral RNA mutations. To date, few antiviral drugs have been authorized for emergency use, but not yet approved, to treat mild to moderate COVID-19, with serious drawbacks and side effects. Antimicrobial peptides (AMPs) play an important role in the host's innate and adaptive immune system against a wide range of microbial infections. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) is thought to be used to increase the recombinant biosynthesis of AMPs. There have been studies that reported the production of AMPs using CRISPR. Therefore, CRISPR is expected to play an important role in the production of AMPs as next-generation, safe, affordable, and efficient antiviral drugs in general and for the treatment of COVID-19 in particular, in addition to AMPs being efficient immunomodulators.
Keyphrases
- sars cov
- coronavirus disease
- genome editing
- crispr cas
- genome wide
- respiratory syndrome coronavirus
- immune response
- emergency department
- escherichia coli
- pseudomonas aeruginosa
- public health
- biofilm formation
- staphylococcus aureus
- microbial community
- healthcare
- cell free
- gene expression
- cell wall
- antimicrobial resistance
- combination therapy
- case control
- nucleic acid